Indivior PLC (INDV, INDV.L) announced that its subsidiaries Indivior Inc. and Indivior UK, entered into a settlement agreement with Actavis Laboratories UT, a unit of Teva Pharmaceuticals, to resolve patent disputes regarding Actavis's Abbreviated New Drug Application for generic buprenorphine and naloxone sublingual film.
By Christian Moess Laursen Indivior said the U.K. high court has removed securities claims against the company and Reckitt Benckiser in separate legal cases.
Citigroup Inc. bought a new stake in shares of Indivior PLC (NASDAQ:INDV – Free Report) in the second quarter, HoldingsChannel reports. The institutional investor bought 213,426 shares of the company’s stock, valued at approximately $4,947,000. Other institutional investors and hedge funds have also bought and sold shares of the company. Rathbones Group PLC bought a […]
By Joe Hoppe Indivior said it has extended its relationship agreement with shareholder Scopia Capital Management, extending the board tenure of director.